KRAS and neoplasm: In terms of immune molecules, it was reported that those against the PD-1/PD-L1 checkpoint could improve the survival rates with KRAS-mutant NSCLC patients because KRAS mutations were correlated with tumor immunogenicity and an inflammatory TME (10).